DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (DESTINY BTC01 - D781PC00001)

drug protocol number
D781PC00001
drug sponsor
AstraZeneca
drug study
Trastuzumab-Deruxtecan,Rilvegostomig &Durvalumab
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh).
drug status
Ongoing
drug phase